ERBB2 and breast carcinoma: In fact, dual anti-HER2 therapy has been proven to improve clinical outcomes of metastatic HER2 positive breast cancer though to be refractory to trastuzumab alone, which lead to the approval of pertuzumab for the treatment of HER2 positive breast cancer [11].